We read with great interest the recent communication by Simren et al ,1 reporting a correlation between visceral hypersensitivity and GI symptom severity in functional GI disorders (FGID). Previously, it has been shown that visceral hypersensitivity can be modulated or even induced in animal models, by altering the composition of their gut microbiota with antibiotics or faecal transplantation from IBS donors.2 3 Hence, while a direct link between gut microbiota composition and visceral pain may need to be conclusively established, this holds great potential for translational exploitation in the treatment of IBS and other FGID. Thus far, the potential association between microbiota and abdominal pain in humans has only been investigated in one study that included 15 individuals.4 For this purpose, we studied 159 individuals (average age 59.1, 39.6% men) from the Swedish Population-based Colonoscopy (PopCol) cohort, previously described and with faecal microbiota 16S sequencing data and daily recordings of abdominal pain (number of episodes, duration and intensity) collected over the same period (7.41±7.91 days).5–7 Among these, 52 individuals (assigned to the case group) reported at least one episode …

中文翻译：

---

粪便微生物群组成与普通人群的腹痛有关

我们非常感兴趣地阅读了 Simren 等人最近的通信，1 报告了功能性胃肠道疾病 (FGID) 中内脏超敏反应和胃肠道症状严重程度之间的相关性。此前，已经表明，通过使用抗生素或 IBS 供体的粪便移植来改变肠道微生物群的组成，可以在动物模型中调节甚至诱导内脏超敏反应。 2 3 因此，虽然肠道微生物群组成与内脏之间的直接联系疼痛可能需要最终确定，这在 IBS 和其他 FGID 的治疗中具有转化利用的巨大潜力。迄今为止，仅在一项包括 15 名个体的研究中研究了微生物群与人类腹痛之间的潜在关联。4 为此，我们研究了 159 名个体（平均年龄 59.1、39 岁）。